2026 年 2 月 – 第 26 页

云顶新耀维适平(R)获中国国家药品监督管理局批准上市为中重度溃疡性结肠炎治疗提供新选择

6 2 月, 2026 acn

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，中国国家药品监督管理局（NMPA）已批准维适平(R)（精氨酸艾曲莫德片, VELSIPITY(R)）的新药上市许可申请（NDA），用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。溃疡性结肠炎是一种病因尚不明确、易复发的慢性肠道炎症性疾病。近年来，中国溃疡性结肠炎发病率持续上升，并呈现年轻化趋势，预计患者人数将由2025年的约98万增长至2031年的约150万。疾病对患者生活质量带来长期负担，临床亟需实现更加稳定、持久的疾病控制。作为新一代高选择性S1P受体调节剂，维适平(R)每日一次口服，可实现快速起效和强效深度黏膜愈合，并具有良好的安全性特征，具备最佳药物（best-in-disease）潜质，为成人溃疡性结肠炎患者提供新的一线治疗选择。据悉，维适平(R)此次获批，是基于亚洲多中心III期注册临床ENLIGHT UC研究（ES101002）的结果和全球III期注册研究ELEVATE UC（包括ELEVATE UC 52和ELEVATE UC 12研究）的结果。ENLIGHT UC研究是迄今完成的最大规模亚洲中重度活动性溃疡性结肠炎患者的III期注册临床研究，总计纳入340名患者。结果显示，维适平(R)治疗组在所有主要和次要疗效终点上均达到统计学显著性与临床意义，且安全性良好。研究结果已发表于国际顶级学术期刊柳叶刀子刊《The Lancet Gastroenterology & Hepatology》。从临床价值来看，维适平(R)凭借每日一次口服的治疗方案，能够快速起效并达到临床缓解，同时还在黏膜愈合和组织学改善等方面疗效显著，同时安全性良好。对此，中华医学会消化病学分会前任主任委员、炎症性肠病学组组长、中山大学附属第一医院消化内科学术带头人、首席专家陈旻湖教授指出，我国目前正处于溃疡性结肠炎发病率和患病率快速上升阶段，该疾病常反复发作，严重影响患者生活质量，对个人、家庭和医疗资源造成沉重负担。实现黏膜愈合有助于更有效地控制症状，降低复发风险，改善患者生活质量。黏膜愈合是国内外临床指南公认的溃疡性结肠炎治疗目标，这不仅关系到疾病的长期症状缓解，也与改善患者生活质量密切相关。维适平(R)亚太临床试验牵头研究者、世界胃肠病组织执委兼司库、亚太地区消化病学会副主席、中华医学会消化病学分会第十、十一届副主委、空军军医大学西京消化病医院吴开春教授指出，长期以来，我国溃疡性结肠炎治疗面临传统疗法疗效有限、给药便捷性差以及不良反应多等诸多局限。已获批的生物制剂和小分子治疗也存在"疗效天花板"及"失应答"等问题。维适平(R)通过调控淋巴细胞迁移，从源头控制肠道炎症，并促进黏膜愈合。在多个临床研究中维适平(R)展现出显著疗效，尤其在快速起效、实现无激素缓解及深度黏膜愈合方面具有明显临床优势。此次获批标志着维适平(R)从临床研究到上市的完整验证，为患者提供创新治疗选择，并推动中重度溃疡性结肠炎管理进入新阶段。云顶新耀董事会主席吴以芳表示："自身免疫性疾病在全球范围内对患者造成长期而深远的影响，在中国乃至全球范围内，仍存在大量尚未满足的临床需求。维适平(R)的获批不仅体现了创新疗法在溃疡性结肠炎治疗中的临床价值，也彰显了公司坚持以国际研发标准推进创新药物发展的长期战略。我们期待通过持续拓展全球化布局，让更多患者受益于高质量、具有突破性的治疗选择。"云顶新耀首席执行官罗永庆表示: "此次维适平(R)在中国的获批，填补了中重度溃疡性结肠炎治疗领域的重要空白，并为以深度黏膜愈合为目标的创新口服治疗提供了新的选择。公司将加快推进维适平(R)的商业化进程，并积极推动纳入国家医保目录，持续提升创新疗法在中国的可及性和可负担性，让更多患者受益。"值得一提的是，维适平(R)的临床价值已获得多项国际权威指南的充分认可，被先后纳入2024年美国胃肠病协会（AGA）临床实践指南及2025年美国胃肠病学院（ACG）临床指南，并获强烈推荐。此前，该药已于2024年和2025年被列入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（文件中名称为"伊曲莫德"）。目前，维适平(R)已在美国、欧盟以及中国大陆、中国香港、中国澳门、新加坡等多个国家和地区获得新药上市批准。2025年3月，云顶新耀启动维适平(R)嘉善工厂建设项目，为本地化生产及长期可及性提供有力支持。维适平(R)的成功获批，进一步夯实了云顶新耀在自身免疫疾病领域的产品布局，也是公司2030年发展战略的重要组成部分。该战略以"BD合作 + 自主研发"双轮驱动为核心，致力于通过商业化实现确定性价值，同时通过持续创新研发构建长期成长动能，推动管线的延续性与可持续发展。在商业化平台建设上，云顶新耀已布局三款商业化产品，并着力建立全渠道商业化体系及药品全生命周期商业化能力。计划到2028年实现收入规模超过100亿元人民币，而到2030年收入规模超过150亿元人民币（其中现有管线销售收入约90亿元人民币而新引进管线销售收入约60亿元人民币）；收入的年复合增长率预计在2025至2030年超过50%，2030年后保持超过15%。同时，商业化产品数量将提升至20款以上，包括耐赋康(R)、维适平(R)、依嘉(R)、乐瑞泊(R)（莱达西贝普）及MT1013等。业内普遍认为，维适平(R)有望成长为云顶新耀又一重磅产品，其销售峰值预计可达50亿元人民币。随着维适平(R)商业化进程的持续推进，公司整体收入结构与成长曲线有望进一步优化。未来，云顶新耀将继续聚焦重大未满足临床需求，持续强化差异化创新管线，加速推进具有国际竞争力的创新疗法落地，助力公司实现可持续成长，并为患者与社会创造更大的健康价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025

6 2 月, 2026 acn

The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

挪威前首相因涉嫌与Epstein相关的“腐败”被调查

6 2 月, 2026 admin

(SeaPRwire) - 新公布的文件显示，托尔比约恩·亚格兰曾致信这位声名狼藉的金融家，提及“非凡的女孩” 挪威已对前首相托尔比约恩·亚格兰展开调查，怀疑其因与声名狼藉的美国金融家及性犯罪者杰弗里·爱泼斯坦有联系而涉嫌严重腐败。亚格兰于1996年至1997年担任挪威首相。2009年至2019年，他担任欧洲委员会秘书长；2009年至2015年，他担任挪威诺贝尔委员会主席。挪威反腐败机构Okokrim在周四的一份声明中表示，已要求外交部取消亚格兰作为前外交官享有的豁免权。Okokrim负责人帕尔·朗塞斯称，调查将聚焦于亚格兰是否利用其职位收受礼物或好处。这位资深政治家在美国当局上周公布的爱泼斯坦遗产相关文件中被多次提及。在2012年5月致爱泼斯坦的一封电子邮件中，亚格兰写道：“我在阿尔巴尼亚地拉那遇到了非凡的女孩。”在2013年1月的另一封邮件中，这位前首相提及计划与妻子和儿子一起访问爱泼斯坦在加勒比海的私人岛屿，并补充道：“你知道的，我不能只和年轻女性一起继续下去。” 周一，亚格兰告诉报纸VG，这些邮件包含“令人尴尬的行话”，可能会被误解，并表示他从未在没有妻子陪同的情况下访问过爱泼斯坦的房产。他否认曾在爱泼斯坦的岛上停留过。亚格兰的律师安德斯·布罗斯维特表示，他将向调查人员提交所有相关信息。“根据我们目前发现的情况，我们对结果有信心，”布罗斯维特告诉路透社。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

「工业数智化引擎」卡奥斯冲击港交所激活制造业新动能

6 2 月, 2026 acn

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 在全球制造业进入「再工业化」与「数字化重构」并行的新阶段，工业数智化已不再是可选项，而是企业提升长期竞争力的必选项。卡奥斯物联科技股份有限公司（「卡奥斯」），正是这场产业变革的引领者。根植于海尔集团40余年智能制造积淀与大规模定制模式创新实践，卡奥斯以工业大模型驱动的COSMOPlat平台为核心，早已突破传统解决方案供应商的边界，进化为开放、协同、不断自我进化的工业数字生态的构建者。 1月30日，卡奥斯正式向港交所递交上市申请，旨在通过港股上市，将其工业数智化能力，带向更广阔的全球市场。技术赋能产业：COSMOPlat 引领工业转型升级从行业层面看，工业数智化正处于由「系统建设期」向「平台扩展期」过渡的关键阶段。根据Frost &Sullivan数据，2024年，中国工业数智化解决方案市场规模达到2.0万亿元。相比一次性交付的项目模式或单一解决方案销售，基于工业大模型与智能体技术的工业互联网平台，能够通过能力沉淀和模型复用，实现跨系统的数据接入与统一治理，获得更高的边际效率与更强的客户黏性，其优势将持续凸显。卡奥斯的核心竞争力，正在于其自主开发的COSMOPlat工业互联网平台，其构建了工业智能软件与智能体应用、工业作系统与工业大脑、物联系统与边缘计算深度融合的一体化技术架构，以端云一体的数据智能与物联网产品及解决方案，全方位赋能企业数智化转型。COSMOPlat平台以工业大模型核心驱动力，该模型为国内首个基于工业互联网平台的工业大模型，依托海尔集团40余年制造业经验、天数工业大数据平台积累的专家模型与高质量多模态数据集研发而成，可支持研发设计、生产制造、运营服务、双碳管理等主要工业场景的数智化。基于天智工业大模型，卡奥斯将智能体应用与工业场景充分融合，打造了覆盖3大行业、40余个核心场景的工业智能体，帮助客户缩短研发周期、提高生产效率、降低用能成本。卡奧斯依託工業互聯網平台，將製造業全流程解構為需求交互、研發、營銷、採購、生產、物流、服務七大模塊，把復雜流程封装為可複製、可推廣的工業智能軟件與端雲一體化解決方案，有力支撐跨行業、跨領域推廣應用，实现从「服务单个企业」到「激活整个产业集群」的价值跃升。目前，卡奥斯已与家电、能源化工等行业的一批龙头企业、专精特新企业和园区客户建立战略合作，共同探索基于工业互联网平台的数智化转型新路径，为客户打造17座灯塔工厂，全球数量最多、覆盖行业最广。不仅如此，标杆项目的示范效应还能带动公司快速切入新行业、获得新客户，形成老客户复购与新客户引流的扩散效应，从单一产品的复购延伸至全链条服务，实现从「单点赋能」到「全场景绑定」，增厚公司业绩弹性。截至2025年9月，卡奥斯已累计链接企业超16万家，其中付费企业达9500余家，生态规模与商业价值同步提升。全球布局：中国方案的世界表达卡奥斯的另一大看点，是其作为中国工业智能化「方案输出者」的全球定位。作为中国工业互联网平台出海的先行者，卡奥斯正将成熟的数智化模式推向全球，成为中国智造「走出去」的核心载体。截至2025年9月30日，卡奥斯的解决方案已在全球16个国家推广，在美国、新西兰、意大利等国家的70余座工厂成功落地。在东南亚，其布局的智能控制器研发制造中心正快速渗透当地电子制造产业链; 在北美，凭借服务海尔集团海外家电互联工厂的经验，公司成功切入当地智能家居领域。卡奥斯全球化布局的独特之处在于，它不是简单的市场扩张，而是一种更高维度的「软实力」出海，即将其在国内经过验证的工业数智化模式进行全球输出。 2025年前3季度，公司海外收入占比超12%，形成稳定的海外增长曲线。更为深远的影响体现在国际标准制定领域。卡奥斯是首家被IEEE、ISO、IEC和UL四大国际标准组织共同批准主导制定工业互联网和大规模定制国际标准的平台，也是首个被欧洲联邦云（GAIA-X）邀请参与共建平台的非欧盟企业，累计主导、参与制定国际标准12项，国家行业标准98项。通过将技术优势转化为国际规则，卡奥斯为中国在全球工业数字化领域赢得了重要话语权，为后续全球化扩张铺平道路。卡奥斯赴港上市，恰逢全球制造业加速智能化转型、中国数字经济与实体经济深度融合的关键时期。凭借以AI技术赋能的工业互联网平台，卡奥斯已积累庞大用户基础，更以中国方案输出模式推进全球化布局，持续拓宽增长边界。平台能力、生态结构与全球复制经验的叠加，让卡奥斯早已超越单一工业互联网服务商的定位，进化为未来工业生态的构建者和中国智造出海的标杆。随着生态成员的持续扩容、国际标准话语权的深化以及新兴市场的加速渗透，卡奥斯的成长潜力将持续释放。对于关注中国科技出海与全球制造业复苏的国际资本而言，卡奥斯不仅是分享工业数智化红利的优质标的，更有望凭借中国工业技术与生态模式，在全球工业变革浪潮中书写生态共荣、价值共创的全新篇章。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market

6 2 月, 2026 jcn

All-new Versa VanTOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Mitsubishi Motors Philippines Corporation (MMPC), a subsidiary of Mitsubishi Motors in the Philippines, began sales of the all-new Versa Van on February 6. The model is an OEM-supplied commercial vehicle by Nissan Motor Co., Ltd. (hereafter, Nissan).The all-new Versa Van offers five-row seating for up to 15 passengers and features a spacious interior optimized for transporting people, supporting a wide range of commercial applications, including shuttle services. Powered by a 2.5-liter inline four-cylinder diesel engine, the model delivers strong torque from the moment of acceleration, ensuring confident performance even when carrying many passengers or driving on steep inclines. With this new model, Mitsubishi Motors aims to strengthen its commercial vehicle lineup in the Philippines and meet customer needs alongside the existing L300 model.As Alliance partners, Mitsubishi Motors and Nissan are pursuing global collaboration in areas such as joint development and production of next-generation pickup trucks, as well as joining forces to drive business expansion in electrified vehicles. The OEM supply of the all-new Versa Van by Nissan for the Philippine market represents a tangible outcome of this collaboration. Mitsubishi Motors has also begun supplying Nissan with the Rogue Plug-in Hybrid for North America and the Navara for Oceania and has been supplying the Livina to the Philippine market since 2022 — an initiative that improves plant utilization and complements model lineups, building a mutually beneficial partnership. Furthermore, Mitsubishi Motors will receive OEM supply of an all-new EV model derived from Nissan’s new LEAF in 2026 and will introduce the model to the North American market in the latter half of the year.Mitsubishi Motors will continue to leverage diverse partnerships to expand its product lineup, strengthen regional operations, and accelerate initiatives that enhance profitability.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market

6 2 月, 2026 acn

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Eternal Beauty Holdings Limited (“Eternal Beauty” or the “Group”) (Stock Code: 6883.HK), a pioneer in China’s beauty and fragrance industry, announced its first-ever collaboration with Lane Crawford, a premier luxury department store, to launch an exclusive boutique niche fragrance section at its Harbour City store in Tsim Sha Tsui. The collaboration aims to further advances the Group’s strategy focused on high-margin niche fragrance brands, strengthens its premium brand footprint through an elite retail network, and captures the growing profit opportunities in the niche fragrance for Chinese Mainland and Hong Kong markets.The zone brings together four international niche fragrance brands under the immersive concept of a "Luxury Niche Perfume Street" with European flair, featuring Atkinsons, Clive Christian, Memo Paris and SOLFÉRINO, each presented with its unique style and heritage. Clive Christian and SOLFÉRINO are making their debut in Hong Kong, offering a rare experience to local high-end consumers. By leveraging Lane Crawford’s premium retail network that reaches high-spending customers, the Group effectively enhances brand penetration in the Hong Kong market. This initiative successfully introduces the Group’s portfolio into a core upscale retail destination in Hong Kong, demonstrating the Group’s strengths in channel expansion and retail curation, while further solidifying its brand influence and long-term growth momentum in the niche fragrance portfolio.Brand Introduction:AtkinsonsThe 200-year-old British "Royal Fragrance House" reinvents the rebellion and elegance of 19th-century English gentlemen, transforming historical formulas into a modern, contemporary aura.Clive ChristianThe first exclusive collectors’ boutique in Hong Kong: Clive Christian is a luxury British perfume house that creates the world's finest perfumes. A legacy of British craftsmanship, unparalleled quality in concentration and complexity, unashamedly indulgent and luxurious presentation.Memo ParisMemo Paris is a Parisian fragrance house, see each fragrance as a travel note captured in scent. Preserve memory of a journey to unique destination. Memo Paris sketches a delicate, emotional map of the world: a universe where memories become scents.SOLFÉRINODebuting brilliantly in Hong Kong, SOLFÉRINO is born in Paris, France, the brand draws inspiration from the historic architecture of this City of Lights, showcases French elegance with exceptional craftsmanship and presenting Parisian audacity and creativity.Ms. Wendy Lau, Executive Director of Eternal Beauty and Chairman of the International Fragrance Association, said, “With over 40 years of industry experience, Eternal Beauty has cultivated sharp market vision, distinctive taste, and profound expertise. This enables the Group to accurately identify and introduce brands that align with market trends and carry strong profit potential into the Greater China market, which continues to demonstrate vigorous consumption upgrade momentum. We are thrilled to partner with Lane Crawford, an influential luxury department platform in Asia, to create this exclusive boutique niche fragrance section in Hong Kong’s core luxury shopping district, leveraging the Group’s strengths in niche fragrance brand management and retail channel development. This is not only an important step for the Group to deepen the niche fragrance market, but also a concrete manifestation of our niche fragrance brand expansion strategy. Moving forward, the Group will continue to explore collaborations with top-tier retail partners. By introducing more niche brands with high growth potential, it will strengthen its long-term growth momentum and enhance sustainable profitability in the fragrance market.”Hong Kong's fragrance market continues to benefit from the momentum of the emotional economy, demonstrating relatively resilient growth against the backdrop of a steady recovery in the overall retail sector. In December 2025, the value of total retail sales in Hong Kong increased by 6.6% YoY; according to market’s outlook reports, the total retail sales in Hong Kong are expected to grow by nearly 8% in 2026, reaching approximately HKD 410 billion, indicating a continued recovery in local consumer demand. Ms. Chole Lam, Executive Director and Chief Executive Officer of Eternal Beauty, said, “In recent years, experiential retail and emotional consumption have gradually emerged as new retail trends, with emotional value playing an increasingly significant role in consumer decision-making. The ability to establish emotional resonance with consumers is becoming an important direction for brand expansion and product innovation. Emerging consumption segments, represented by high-end and niche fragrances, are more being regarded as categories that carry emotional value and lifestyle propositions, highlighting their growth potential in the retail recovery process.”Eternal Beauty has established an omni sales channel network over 400 cities across Chinese Mainland, Hong Kong and Macau. The cooperation with Lane Crawford is an important part of the Group’s retail channel strategy, aiming to enhance the consumer experience and sales conversion by leveraging the prime location and high customer traffic of the premium department store.Photo CaptionEternal Beauty and Lane Crawford debut landmark niche fragrance zone, bringing together four international niche fragrance brands under the concept of a "Luxury Niche Perfume Street". The zone immersively showcasing four distinctive and heritage-rich brands: Atkinsons, Clive Christian, Memo Paris, and SOLFÉRINO.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharingAbout Eternal Beauty Holdings LimitedEternal Beauty Holdings Limited is the largest perfume group (apart from brand-owner perfume groups) in China (including Hong Kong and Macau) in terms of retail sales in 2023. It primarily sells and distributes products procured from third-party brand licensors, and deploys market for these brand licensors, offering such services as brand management, and designing and implementing customized market entry and expansion plans for their brands. The Group boasts large and diversified brand portfolios that include not only perfumes, but also color cosmetics, skincare products, personal care products, eyewear and home fragrances. As at 30 September 2025, it conducted product distribution and market deployment for a total of 74 external brands, including Hermès, Van Cleef & Arpels, Chopard, Albion and Laura Mercier, with products in different pricing tiers and of versatile features that meet the differentiated demands of consumers in Chinese Mainland, Hong Kong and/or Macau. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

颖通控股与连卡佛携手打造首个顶级小众香水殿堂进一步拓展高毛利小众香氛市场版图

6 2 月, 2026 acn

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 中国香水产业领航者颖通控股有限公司（「颖通控股」或「集团」）（股份代号：6883.HK）宣布与顶级奢侈品百货连卡佛达成首度合作，于尖沙咀海运大厦连卡佛内设立首个小众香水限定专区，进一步落实集团聚焦高毛利小众香水品牌的发展策略，并透过顶级零售网络深化高端品牌布局，把握中国内地及香港高端香氛市场持续增长所带来的盈利机遇。专区云集四大国际高端香氛品牌，以充满欧洲风情的「高级小众香水街」为概念，沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。Clive Christian 及 SOLFÉRINO 更是首度登陆香港，为本地高端消费者带来独家体验，并藉助连卡佛覆盖高消费客群的优质零售网络，有效提升品牌在香港市场的渗透率，进一步将集团旗下品牌引入香港核心高端零售据点，展现集团在渠道拓展与零售策展方面的实力，巩固于高端香氛市场的品牌影响力及长期增长动能。品牌介绍：Atkinsons拥有二百年历史来自英国的「皇室御用香氛品牌」，重塑十九世纪英伦绅士的叛逆与优雅，将历史配方化为现代摩登气息。Clive Christian香港首间典藏级专柜：源自英国伦敦的 Clive Christian 被誉为「世界最奢华的香水之一」，致敬英国皇室贵族经典与顶级奢华工艺传承，彰显无可比拟永恒优雅的底蕴。Memo Paris来自法国的 Memo Paris 以旅行与记忆为灵感，以香气铭记旅途故事，绘制一幅诗情画意的香氛情感地图，将世界景致汇聚于瓶中。SOLFÉRINO首次于香港耀目登场的 SOLFÉRINO 诞生于法国巴黎，灵感源自这座光之城的历史建筑，以精湛工艺诠释法式优雅，创作前卫而富创意的香气。颖通控股执行董事及国际香氛协会主席刘颕贤女士表示：「凭借四十余年的行业经验，颖通积累了敏锐视野、独到品味与深厚专业知识，得以精准甄选契合市场趋势且具备盈利潜力的品牌，并引入蕴藏巨大消费升级动能的大中华市场。我们很高兴与亚洲具影响力的奢侈品百货连卡佛携手，在香港核心奢侈品商圈打造首个小众香水专区，充分发挥颖通在高端香氛品牌运营与零售渠道布局方面的专长。这不仅是集团深化小众香水市场的重要一步，更是我们高端香氛品牌布局策略的具体实践。未来，集团将持续探索与顶级零售伙伴的合作机会，引入更多具高成长潜力的小众品牌，进一步强化集团在高端香氛市场的长期增长动能与可持续盈利能力。」香港香氛市场持续受惠于情绪经济带动，在整体零售业稳步复苏的环境下，展现出相对强韧的增长势头。2025年12月，香港零售业总销货价值按年上升6.6%；而根据市场展望报告预测，2026年香港零售总额有望增长近8%，达到约4,100亿港元，显示本地消费需求正持续回暖。颖通控股执行董事兼首席执行官林荆女士表示：「近年，体验式零售和情绪消费渐成为零售新潮流，情绪价值在消费决策中的比重明显提升，能否与消费者建立情绪共鸣，正日益成为品牌拓展与产品创新的重要方向。以高端与小众香氛为代表的新兴消费板块，愈来愈多地被视为承载情绪价值与生活方式主张的品类，显示其在零售复苏进程中的增长潜力。」颖通控股已建立覆盖中国内地、香港及澳门逾400个城市的全渠道销售网络，是次与连卡佛的合作为集团零售渠道升级策略的重要一环，旨在透过高端百货的黄金地段与客流量，提升品牌消费体验与销售转化。图片说明颖通控股与连卡佛合作开设首个小众香水专区，云集四大国际高端香氛品牌，以充满欧洲风情的「高级小众香水街」为概念，沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。请通过此链接下载更多高清图片：https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharing关于颖通控股有限公司颖通控股有限公司是中国（包括香港及澳门）最大的香水集团（除品牌所有者香水集团外，按2023年零售额计），主要从事销售及分销从第三方品牌授权商采购的产品及为该等品牌授权商进行市场部署，例如为其品牌设计及实施定制的市场进入及扩张计划。颖通控股拥有庞大且多元化的品牌组合，不仅包括香水，还包括彩妆、护肤品、个人护理产品、眼镜及家居香氛。截至2025年9月30日，颖通控股为合共74个外部品牌进行产品分销及市场部署，包括 Hermès、Van Cleef & Arpels、Chopard、Albion及Laura Mercier，涵盖多元化的定价层次及功能，迎合中国内地、香港及或澳门消费者的差异化需求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors

6 2 月, 2026 acn

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On February 6, Distinct Healthcare Holdings Limited ("Distinct Healthcare" or the "Company", Stock Code: 2677.HK), a leading player in China's mid-to-high-end consumer healthcare services market, was successfully listed on the main board of the Hong Kong Stock Exchange, emerging as a high-quality and rare private healthcare gem in the Hong Kong stock market. This marks the beginning of a new chapter in the Company's scaled and high-quality development.On its debut, Distinct Healthcare delivered a standout debut, opening sharply higher at HK$81 per share (a 35.23% premium to the offer price), well above the offer price—an indication of strong capital market recognition of the Company's growth potential. The active trading and high investor enthusiasm further corroborate the market's firm confidence in the consumer healthcare services sector and the Company's core value.Possessing a Large Customer Base with Continuously Improving ProfitabilityAs the third-largest provider of private mid- to high-end healthcare service in China, Distinct Healthcare has always adhered to its patient-oriented core principle, placing patient well-being at the forefront. This approach has enabled the Company to gradually build a large and high-quality patient base, leading the industry in both user scale and return rate.From 2022 up to the eight months ending 31 August 2025, the total number of patients served by its healthcare institutions in China rose from 162,393 to 212,180, and the total number of paid patient visits of its healthcare service institutions and tele-healthcare service platform grew from 529,829 to 642,132.Patient loyalty has continued to rise, with the patient return rate steadily climbing. In 2022, 2023, 2024 and the eight months ended 31 August 2025, the patient return rates reached 75.7%, 78.2%, 80.0% and 82.7%, respectively. This robust growth is a strong testament to the market and patients' high recognition of Distinct Healthcare's service quality.Leveraging its large and high-quality customer base and the advantages of its standardized medical services, Distinct Healthcare has achieved steady business growth "without relying on medical insurance subsidies or excessive marketing expenditure". Financial data shows the Company's total revenue increased steadily from RMB473 million in 2022 to RMB959 million in 2024, doubling its revenue in two years and achieving a compound annual growth rate (CAGR) of 42.3%, demonstrating strong growth momentum.In terms of profitability, the Company achieved a critical milestone by turning profitable in 2024, with an adjusted net profit of RMB10.7 million. This represents a qualitative leap from scale-driven growth to profitability-driven growth.Strong Line-up of Cornerstone Investors and Clear Strategic Plan Support High-Quality DevelopmentDistinct Healthcare has attracted a strong roster of cornerstone investors in this IPO, including Health Vision, Kingmed Diagnostics, Mininglamp Technology, and Galaxy Dynasty. Together, they subscribed for a total of approximately HK$90.7876 million. The active participation of these renowned, high-quality institutional investors fully reflects their high recognition of Distinct Healthcare's core competitiveness, business model, and future development prospects, and will also provide powerful resource support and brand endorsement for the Company's subsequent development, helping it to further expand its industry influence.Regarding the use of IPO proceeds, Distinct Healthcare has formulated a clear strategic plan to ensure the proceeds are effectively deployed to support the Company's high-quality growth. Approximately 35% of the net proceeds will be allocated to digitalization and intelligent upgrades. By building a professional talent pool for medical AI applications, establishing strategic partnerships with leading research institutions and technology companies and making external procurements, while leveraging internal IT and data technology departments to iteratively optimize existing IT systems, the Company will deploy advanced AI technologies, optimize medical service workflows and enhance diagnostic efficiency as well as operational effectiveness.Approximately 30% of the net proceeds will be used for service network expansion and upgrades, primarily focusing on enhancing the diagnostic environment and equipment at existing medical service institutions. It will also advance the layout of new institutions, including relocating an existing institution in Shenzhen and establishing new institutions in key cities such as Hangzhou and Shanghai, thereby further expanding and improving service coverage in key domestic regions.Approximately 25% is earmarked for strategic mergers and acquisitions, acquire high-performing medical service institutions with strong synergies in first-tier and new first-tier cities when suitable opportunities arise, aiming to rapidly expand market share and strengthen regional competitiveness. The remaining approximately 10% will be used as working capital and for general corporate purposes, providing stable financial support for daily operations and business expansion.This clear strategic roadmap not only charts a clear course for the Company's future growth, effectively enhancing its core competitiveness and sustainability, but will also further reinforce its leading position in China's private mid-to-high-end healthcare sector. It will help propel the Company to new heights, achieving its long-term goals of scaled and high-quality development.This successful listing on HKEX represents a significant milestone in Distinct Healthcare's development journey, marking its official entry into a new phase driven by both "capital and industry". It will further elevate the Company's brand influence and financing capabilities, injecting powerful momentum for its future growth.Moving forward, Distinct Healthcare will remain true to its founding aspirations, staying focused on the mid-to-high-end healthcare services segment. It will continue to enhance medical service quality and patient experience, further unlock its growth potential and deliver sustainable long-term returns to its shareholders. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Establishment of the World’s First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony’s High-Performance Products

6 2 月, 2026 jcn

TOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Sony Corporation (Sony), Mitsubishi Corporation, ADEKA CORPORATION , CHIMEI Corporation, ENEOS Corporation, Formosa Chemicals & Fibre Corporation, Hanwha Impact Corporation, Idemitsu Kosan Co., Ltd., Mitsui Chemicals, Inc., Neste Corporation, Qingdao Haier New Material Development Co., Ltd., SK Geo Centric Co., Ltd., Toray Industries, Inc., and Toray Advanced Materials Korea Inc. have jointly established the world’s first global supply chain consisting of fourteen companies across five countries and regions for the production of renewable plastics*2 that can be used in Sony’s high-performance audio-visual products. The various plastic materials manufactured through this supply chain are slated for use in Sony’s products that will be launched worldwide.＜Overview of the Entire Supply Chain＞(1) Production of renewable naphtha — Neste Corporation / (2) Production of renewable styrene monomer — Idemitsu Kosan Co., Ltd. / (3) Production of renewable polystyrene resin — Formosa Chemicals & Fibre Corporation / (4) Production of renewable para-xylene — SK Geo Centric Co., Ltd. / (5) Production of renewable para-xylene — ENEOS Corporation / (6) Production of renewable terephthalic acid — Hanwha Impact Corporation / (7) Production of renewable PET resin — Toray Advanced Materials Korea Inc. / (8) Production of renewable bisphenol-A — Mitsui Chemicals, Inc. / (9) Production of renewable polycarbonate (PC) resin — CHIMEI Corporation / (10) Production of renewable flame retardants — ADEKA CORPORATION / (11) Production of renewable PC/ABS resin — Qingdao Haier New Material Development Co., Ltd./ (12) Molding manufacturers / (13) Design and manufacturing of finished products — Sony CorporationHigh-performance products such as audio-visual equipment involve a wide variety of plastics, resulting in a complex supply chain that makes it difficult to visualize and manage the entire flow from raw materials. Additionally, plastic components that require high performance in terms of flame resistance and optical properties cannot be fully replaced with plastics produced through material recycling*3, hindering the further reduction of virgin fossil-based plastics in such products.To address these challenges, the fourteen companies collaborated to visualize the existing supply chain for Sony’s products, and created a new supply chain that enables the production of multiple types of renewable plastics from biomass resources with a mass balance approach*4. This allows Sony to proactively source raw materials for its products with the quality and properties equivalent to virgin fossil-based plastics. Defining the supply chain helps the companies track and document GHG (Greenhouse Gas) emissions data over the supply chain in a verifiable way, allowing participating companies to leverage the data to advance efforts to reduce their carbon footprint going forward.This initiative involving wide-ranging partners is part of the ‘Creating NEW from reNEWable materials' project, jointly launched by Sony, which aims to achieve zero usage of virgin fossil-based plastics through the introduction of renewable plastics, and Mitsubishi Corporation.Sony, Mitsubishi Corporation, and the supply chain partners will continue to actively promote the introduction of renewable plastics for high-performance products such as audio-visual products.About ProjectProject Introduction Video：https://youtu.be/3ba3t356sHI[About Sony Corporation]Sony Corporation is a wholly-owned subsidiary of Sony Group Corporation, responsible for the Entertainment, Technology & Services (ET&S) business. With the mission to "create the future of entertainment through the power of technology together with creators", we aim to continue to deliver Kando* to people around the world. Sony is actively promoting initiatives to reduce environmental impact as part of the Sony Group’s "Road to Zero" environmental plan, which aims for zero environmental impact by 2050. In this project, Sony will oversee the entire supply chain and promote the utilization of renewable plastics in our products. https://www.sony.co.jp/en/[About Mitsubishi Corporation]Mitsubishi Corporation (MC) is an integrated trading and investment company that develops and operates businesses across multiple industries together with its global network. MC has eight Business Groups that operate across virtually every industry: Environmental Energy, Materials Solution, Mineral Resources, Urban Development & Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution. Through these eight Business Groups, MC’s activities have expanded far beyond its traditional trading operations to include project development, production, and manufacturing operations, working in collaboration with our trusted partners around the world. In this project, MC plays a comprehensive role in overseeing the supply chain, including credit delivery management, and promoting the introduction of renewable plastics into Sony products. https://www.mitsubishicorp.com/jp/en/[About ADEKA CORPORATION]ADEKA CORPORATION is a manufacturer of valuable materials with over 100 years of history. ADEKA aims to realize a sustainable society by globally expanding valuable materials that enrich people's lives, such as polymer additives that enhance plastic functionality, advanced semiconductor materials, environmental materials, food products, and agrochemicals. In this project, we manufacture flame retardants with biomass characteristics assigned using a mass balance approach. https://www.adeka.co.jp/en/[About CHIMEI Corporation]CHIMEI is a leading high-performance materials company that designs and manufactures advanced polymer materials, synthetic rubbers, and specialty chemicals, delivering innovative and sustainable solutions for industries worldwide. With a commitment to circularity, environmental responsibility, and close client collaboration, CHIMEI supports and partners with global companies to elevate product performance while jointly minimizing environmental impact. In this project, CHIMEI produces polycarbonate resin (PC) with assigned biomass characteristics using a mass balance approach. https://www.chimeicorp.com/en-US[About ENEOS Corporation]At ENEOS Corporation, our network has grown to about 12,000 ENEOS branded service stations across Japan. ENEOS is expanding business to accommodate energy transitions into sources like hydrogen and Synthetic Fuels in addition to petroleum and petrochemical products produced and manufactured at refineries and factories at various locations in Japan. The ENEOS Group aims to achieve both a stable supply of energy and materials and the realization of a carbon-neutral society, based on its commitment of “Supporting ‘today’s normal,’ taking the lead for ‘tomorrow’s normal.’” In this project, ENEOS manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.hd.eneos.co.jp/english/[About Formosa Chemicals & Fibre Corporation (FCFC)]FCFC is a comprehensive chemical company that manufactures petrochemical products, synthetic fibers, and plastics. FCFC implements a circular economy to achieve both environmental protection and industrial development, working on the development of green chemicals and the expansion of reusable materials. In this project, FCFC manufactures polystyrene (PS) with assigned biomass characteristics using a mass balance approach. https://www.fcfc.com.tw/[About Hanwha Impact Corporation]Hanwha Impact is a leading petrochemical and investment company, engaged in chemical products and next-generation energy solutions. Hanwha Impact aims to achieve a sustainable society through developing eco-friendly energy solutions and fostering future innovative technologies. In this project, Hanwha Impact produces high-purity terephthalic acid (PTA) with assigned biomass characteristics using a mass balance approach. https://www.hanwhaimpact.com/[About Idemitsu Kosan Co., Ltd.]The Idemitsu Group is engaged in the development, manufacture, and sales of a wide variety areas of Petroleum, Basic Chemicals, High-Performance Materials, Power/Renewable Energy, and in a variety of fields. Idemitsu Kosan is taking on the challenge of an energy transition to help realize a carbon-neutral and circular society by 2050. In the Basic Chemicals business, we are promoting the use of biomass feedstocks and advancing chemical recycling initiatives. In this project, Idemitsu Kosan produces styrene monomer (SM) using a mass balance approach. https://www.idemitsu.com/en/index.html[About Mitsui Chemicals, Inc.]Mitsui Chemicals is a chemical manufacturer that provides solutions for achieving a sustainable society, offering a wide range of products and services from basic chemicals to high-performance materials. Aiming for carbon neutrality by 2050, the company is working to reduce GHG emissions (Scope 1 and 2) and to maximize its contribution to GHG reductions throughout the entire product life cycle. In this project, Mitsui Chemicals produce biomass-derived bisphenol A (BPA) using the mass balance approach. https://jp.mitsuichemicals.com/en/index.htm[About Neste Corporation]Neste (NESTE, Nasdaq Helsinki) creates solutions for mitigating climate change and accelerating a shift to a circular economy. The company is the world’s leading producer of sustainable aviation fuel (SAF), renewable diesel, and renewable and circular solutions for the chemical and plastics industries. In this project, NESTE supplies renewable naphtha made from waste cooking oil and other renewable raw materials. https://www.neste.com/[About Qingdao Haier New Material Development Co., Ltd.]Haier is a global home appliance manufacturer originating, offering a wide range of products including refrigerators and washing machines. Haier New Materials, a subsidiary of the Haier Group, reduces carbon emissions and promotes the construction of a sustainable society by recycling regenerated plastic materials from disassembled home appliances. In this project, Haier produces recycled PC/ABS blended with a flame retardant with assigned biomass characteristics. https://www.haierdawn-plastics.com/[About SK Geo Centric Co., Ltd.]SKGC is a leading chemical company, offering petrochemical products such as olefins, aromatics and polymers. SKGC is upgrading our portfolio to provide more sustainable products in consumer’s daily lives. In this project, SKGC manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.skgeocentric.com/[About Toray Industries, Inc.]Toray Industries, Inc., is a global leader in advanced materials innovation, comprising more than 300 affiliated companies and approximately 48,000 employees worldwide. Since 1926, Toray Industries have continuously expanded our business portfolio—from Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment. April 2026 marks the 100th anniversary of Toray’s founding. In line with our Corporate Philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products,” we will commit to delivering fundamental solutions to global-scale challenges. https://www.toray.com/ [About Toray Advanced Materials Korea Inc.]TAK is a comprehensive chemical manufacturer, offering various products from daily life to high-end industries. With consistent investing and innovation, TAK provides material solutions for climate crisis. In this project, TAK manufactures PET resin and film with assigned biomass characteristics using a mass balance approach. https://www.torayamk.com *1 In the manufacturing of audio-visual products, this initiative is regarded as a “world’s first” in that it visualizes the entire supply chain from raw materials to finished products and converts raw materials to biomass-based materials at mass-production scale.(Based on research conducted by Mitsubishi Corporation. At the time of announcement in Feb. 2026)*2 Plastics made from renewable biomass resources instead of fossil resources.*3 A method of reusing plastic materials by returning used plastics to their original form through physical processes such as crushing, cleaning, and melting, rather than discarding them.*4 This is a method of allocating the characteristics of specific raw materials, such as biomass resources, to a portion of the product based on the input amount of those materials when they are mixed with non-specific raw materials during the distribution and processing stages from raw materials to products.* "Sony", "SONY" logo and any other product names, service names or logo marks used in this press release are registered trademarks or trademarks of Sony Group Corporation or its affiliates. Other product names, service names, company names or logo marks are trademarked and copyrighted properties of their respective owners and/or licensors.* Visual content in this release may be removed without prior notice due to licensing or copyright reasons.* Kando is a Japanese word that roughly translates to the sense of awe and emotion you feel when experiencing something beautiful and amazing for the first time.MaterialityBased on the Three Corporate Principles, which serve as MC’s core philosophy, MC has continued to grow together with society by contributing to the sustainable development of society through its business activities while pursuing value creation. While continuously creating Shared Value guided by the Materiality, a set of crucial societal issues, MC will continue to strengthen its efforts towards sustainable corporate growth. Guided by this Materiality, MC will continue to strengthen its efforts towards sustainable corporate growth. Out of the six material issues relating to “Realizing a Carbon Neutral Society and Striving to Enrich Society Both Materially and Spiritually”, this project’s activities particularly support “Contributing to Decarbonized Societies” and “Promoting Stable, Sustainable Societies and Lifestyles.”Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

6 2 月, 2026 jcn

TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies. 1 In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world's first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs. 2,3,4,5Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”* Converted at an exchange rate of USD 1 = JPY 155MEDIA CONTACTSEisai Co., Ltd. Public Relations DepartmentTEL: +81 (0)3-3817-5120Shanghai Henlius Biotech Inc.Janice Hanjiayi_han@henlius.comBella Zhouwenting_zhou@henlius.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Shanghai Henlius Biotech Inc.Venus Hu junyan_Hu@henlius.com About SerplulimabSerplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world's first anti-PD-1 antibody to be used as a first-line treatment for ESSCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru). Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Shanghai Henlius Biotech, Inc.Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.References1. Issafras H, Fan S, Tseng C-L, Cheng Y, Lin P, Xiao L, et al. (2021) Structural basis of HLX10 PD1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS ONE 16(12): e0257972. https://doi.org/10.1371/journal.pone.02579722. National Cancer Center Japan, Cancer Information Service, Cancer Statistics (Japanese only) https://ganjoho.jp/reg_stat/statistics/stat/cancer/index.html Last accessed: January 2026.3. Sabari, J., Lok, B., Laird, J. et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14, 549–561 (2017).4. Fujiyoshi K, Yamamoto G, Takenoya T et al. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Res. 2017;37(1):239- 247.5. Cancer Statistics in Japan-2025 https://www.fpcr.or.jp/pdf/pamphlet/cancer_statistics_2025.pdf (P30) Last accessed: January 2026. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization

6 2 月, 2026 acn

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On 6 February, Muyuan Foods Co., Ltd. ("Muyuan Foods" or the "Company", Stock Code: 2714.HK), a global leader in the pork industry, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today, marking the beginning of a new chapter in the Company's international development.Powerful Cornerstone Investors Underscore Muyuan’s Industry LeadershipFor this Hong Kong IPO, Muyuan Foods successfully attracted a prestigious lineup of cornerstone investors, including Charoen Pokphand Foods, Wilmar International Limited (Wii Pte. Ltd. and HPRY), Sinochem Hong Kong, Hong Kong Henan AgriInternational, FIL Investment, RBC Global Asset Management (Asia) Limited and Ping An Life Insurance Company of China, Ltd., and other renowned institutions—14 in total—with combined subscription amounting to US$685 million. This formidable cornerstone investor group not only provides the Company with stable financial support but also brings abundant industrial resources and an international perspective, laying a solid foundation for its subsequent global expansion and valuation enhancement.As a technology-driven pork industry leader, Muyuan Foods has deep expertise cultivated over many years in the industry and has established a uniquely advantageous vertically integrated business model. Its operations comprehensively cover the entire pork industry chain, including hog breeding, hog farming, feed production, as well as slaughtering and meat production. Leveraging synergistic advantages across the entire chain, the Company has steadily maintained its leadership position in the hog farming industry.According to statistics from Frost & Sullivan, since 2021, measured by hog production capacity and hog sales volume, Muyuan Foods has become the world's largest hog farming enterprise. Its hog sales volume has ranked first globally for four consecutive years, solidifying its position as the industry leader. In terms of market share, the Company's global market share steadily increased from 2.6% in 2021 to 5.6% in 2024. As of 2024, this market share already exceeded the combined market share of the world's second to fourth largest participants in the hog farming industry, further widening the gap with peers and continuously highlighting its core competitiveness.Steady Earnings Growth Maintained; Active Overseas Market Expansion Strengthens CompetitivenessRelying on its full industry chain layout and efficient operational management, Muyuan Foods has maintained steady earnings growth in recent years, with profitability continuously improving, demonstrating the Company's operational resilience through solid business data. Data shows that the Company's revenue scale grew steadily from RMB124.826 billion in 2022 to RMB137.947 billion in 2024. Net profit surged significantly from RMB14.933 billion in 2022 to RMB18.925 billion in 2024, indicating remarkable growth and continuously optimized profitability. Entering 2025, the Company's growth momentum further accelerated. In the first nine months of 2025, the Company achieved operating revenue of RMB111.790 billion, a year-on-year increase of 15.5%, and realized a net profit of RMB15.112 billion, a substantial year-on-year increase of 34.4%. The double-digit growth in both revenue and net profit fully demonstrates the Company's strong development momentum and favorable profit outlook.While consolidating its leading position in the domestic market and achieving rapid self-development, Muyuan Foods has consistently anchored its global development strategy, actively expanding into overseas markets. Using the export of technology and equipment as a key approach, it empowers the upgrading of the global hog farming industry and builds an international farming ecosystem. In 2024, the Company entered into a deep strategic partnership with BAF Vietnam Agriculture, providing services including hog house design, biosecurity management, odor control solutions and smart hog farming to help its partner optimize farming efficiency, reduce operational costs, and practice environmentally responsible farming.The smooth progress of this cooperation marks a crucial first successful step for Muyuan Foods in its global layout, accumulating valuable experience for subsequent overseas market expansion. On the other hand, leveraging the vast potential of overseas markets, Muyuan Foods will further achieve optimized resource allocation and efficient synergy on a global scale, continuously broadening its corporate growth boundaries and diversifying profit sources, thereby solidifying its core advantages and enhancing comprehensive competitiveness.Overall, the successful listing in Hong Kong not only signifies that Muyuan Foods has formally entered a new stage of internationalized development, establishing an important bridge connecting global capital and resources, but also indicates that the Company's operational management level, industry competitiveness, and development potential have gained broad recognition from the international capital market. In the future, Muyuan Foods will seize this listing opportunity, adhere to the philosophy of technology-driven and green development, continue to deepen its involvement in the entire pork industry chain, constantly strengthen its core competitiveness, steadily advance its global layout, further consolidate its position as the global leader in the hog farming industry, and open up broader growth space. Its future development is worthy of market anticipation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Fujitsu Japan and JMDC announce collaboration to build sustainable healthcare system in Japan through enhanced medical data utilization

6 2 月, 2026 jcn

Kawasaki and Tokyo, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.This collaboration, which began on January 5, leverages JMDC's expertise in utilizing anonymized medical data and Fujitsu Japan's customer base. Fujitsu Japan holds the top share in the Japanese electronic health record (EHR) market for medical institutions. This synergy will accelerate the utilization of medical data by medical institutions and organizations that are part of the healthcare system, while also supporting data-driven management decision-making.This collaboration will see the two companies combine Fujitsu Japan's knowledge in the medical field and advanced technologies including AI, with JMDC's prediction models based on insurance user data and its expertise cultivated through Pep Up, one of Japan's largest personal health record services used by 7.7 million people. This will expand the scope of data utilization from DPC data [1] to comprehensive EHR data. This initiative will further promote the utilization of medical data, contributing to improved management for medical institutions and advanced research for pharmaceutical companies, government agencies, and academia.Going forward, Fujitsu Japan will contribute to the realization of digital hospitals that promote DX in medical institutions, while JMDC will advance initiatives that contribute to "building a sustainable healthcare system through addressing social issues with the power of data and ICT" and "accelerating the societal integration of data."Overview of the collaborationFujitsu Japan will provide Dashboard 360, a solution that enables visualization and analysis of management and clinical data, free of charge [2] to medical institutions that agree to provide anonymized DPC data [3]. Dashboard 360 is offered as part of Fujitsu Limited's Uvance business model, which addresses societal challenges, specifically within the Smart Hospital offering that maximizes hospital operational efficiency and effectiveness. It is a component of the Healthcare Management Platform, a suite of services designed to optimize patient flow [4] in acute care hospitals and support the resolution of management challenges.Dashboard 360 seamlessly integrates with EHRs, allowing for factor analysis of issues such as declining bed occupancy rates and waiting times for hospitalization or surgery, based on information including inpatient care and outpatient conditions leading to hospitalization. It also features a benchmarking function, utilizing data provided by JMDC and DPC data from medical institutions, to support timely decision-making in hospital management.JMDC will collaborate with Fujitsu Japan to anonymize DPC data in a secure environment and provide it to pharmaceutical companies, government agencies, and universities for research purposes. Additionally, by combining this with JMDC's accumulated insurance user data, covering approximately 20 million individuals, the collaboration will visualize the entire patient journey from pre-onset abnormal test results to inpatient treatment and post-discharge prognosis. This will enable early detection of diseases through screening of potential patients, prevention of severe cases by identifying risk factors, and precise evaluation of long-term treatment effects and drug safety in real-world settings, thereby contributing to the improvement of medical quality and efficiency.Figure: Collaboration overviewBackgroundIn Japan, the aging population and increasing medical expenses are pressing concerns. Challenges such as a shortage of healthcare professionals and financial difficulties for medical institutions persist. By leveraging medical data, it is expected that these challenges can be addressed through improved diagnostic accuracy, enhanced operational efficiency, development of new treatment methods, and strengthened regional healthcare collaboration.[1] DPC data:Data used to calculate medical costs based on the patient's diagnosis and treatment content during hospitalization. It includes patient information, diagnoses, surgical procedures, medications used, and is expected to be utilized for analyzing medical quality and hospital management, as well as for formulating healthcare policies.[2] Agreement to provide anonymized DPC data:Fujitsu Japan is entrusted by medical institutions with the creation of anonymized information such as DPC data, and the medical institutions grant Fujitsu Japan permission for secondary use of the created anonymized information.[3] Free of charge:No initial setup or usage fees. A separate license fee for the BI tool included in the service is required.[4] Patient flow:The management of the entire patient process from hospital visit to discharge.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout JMDCEstablished in 2002 as a pioneer in the medical big data industry, JMDC possesses proprietary anonymization processing technology and data analysis/aggregation technology. Based on the analysis of over 1.573 billion medical claims data and over 76 million health checkup data (as of March 2025), JMDC provide information services, including support for health promotion programs for payers, drug safety evaluation, and healthcare economics analysis. JMDC is committed to realizing a healthy society through medical data and analytical capabilities, providing a single index for health (Health Age) and web services for health promotion (Pep Up), among others. Find out more: https://www.jmdc.co.jp/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesJMDC Inc.JMDC Inc. IR OfficeEmail: jmdc-pr@jmdc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Genesys and Fujitsu Transform AEON Financial Service’s Contact Center Operations with Genesys Cloud Delivers Customers an Improved Self-Service Experience Resulting in Higher Completion and Reduced Wait Times

6 2 月, 2026 jcn

Tokyo and Kawasaki, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Genesys® Cloud Services, Inc. (Headquarters: Minato-ku, Tokyo; President: Paul Ito Ricci, hereinafter Genesys), a global cloud leader in AI-Powered Experience Orchestration, and Fujitsu Limited (Headquarters: Kawasaki City, Kanagawa Prefecture; President and CEO: Takahito Tokita; hereinafter Fujitsu) which led the implementation of Genesys Cloud, announced the successful transformation of AEON Financial Service Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Tomoharu Fukayama; hereinafter AEON Financial Service) contact center operations and the completion of its effectiveness evaluation.As part of this contact center transformation initiative, AEON Financial Service deployed Genesys Cloud™, a unified experience orchestration platform. Because of the composability of the Genesys Cloud platform, Fujitsu implemented customizations to meet its unique business requirements, including reporting management and system integrations, and will continue to support maintenance and operations. With over 2,500 seats, this deployment is among the largest of its kind in Japan’s financial sector.AEON Financial Service plans to introduce an “AI Concierge (Voice Bot)” utilizing speech recognition technology. This will allow customers to be guided to the appropriate menu through natural spoken dialogue, eliminating the need for phone keypad input. Furthermore, AEON Financial Service is considering expanding the solution to other contact centers across the AEON Group. Genesys and Fujitsu will continue to support the advancement of contact center systems across the entire AEON Group.Paul Ito Ricci, President of Genesys Japan, commented:"AEON Financial Service is demonstrating how modern experience orchestration can transform customer engagement at scale in a short period.By moving its contact center platform to the cloud, the company has been able to internalize system development and significantly accelerate the speed at which it can deliver more convenient services to address customers’ needs. . We are committed to supporting AEON Financial Service through Genesys Cloud as they utilize AI to deliver innovative, personalized and empathic customer experiences and seamless support for each individual at scale."Masaru Yagi, Executive Vice President, Fujitsu Limited, commented:"We are pleased to announce the successful introduction of Genesys Cloud to enhance the contact center operations for AEON Financial Service. This initiative addresses the crucial and growing need for contact center transformation in recent years. We are confident that this project meaningfully contributes to establishing an operator-first environment where high-quality customer experience can be delivered without added burden. Fujitsu will continue to support the implementation and operation of Genesys Cloud as a solution vendor, leveraging AI and other technologies to support AEON Financial Group and many other companies."BackgroundAEON Financial Service call center is responsible for comprehensive support across a wide array of financial services, including banking, insurance, and loans, in addition to payment services such as AEON Pay, AEON Card, and WAON. A significant challenge for the company was the increase in customer waiting times due to the growing variety of inquiry types and the increasing specialization and segmentation of internal guidance points. Moreover, the conventional on-premises call center system required modernization to effectively support future service expansion.Improvements driven by the contact center operations overhaulFollowing the deployment of Genesys Cloud and the overhaul of its contact center operations, AEON Financial Service has realized the following benefits within the first six months:1. Higher self-service completion ratesBy expanding self-service options within the IVR (Interactive Voice Response) system, the self-completion rate for the menu option that allows customers to report payments after a failed withdrawal improved by 21 percentage points compared to the previous system, helping reduce customer wait times.2. Automated SMS supportBy implementing a mechanism that automatically sends an SMS in response to IVR inquiries, simple questions can now be resolved through self-service. This allows operators to concentrate on more complex tasks.3. Rapid feature enhancements and flexible operationsThe use of a cloud service with the requirement of a low-code functionality enables the speedy deployment of new services and quick changes to the IVR structure. Furthermore, future efforts to bring development in-house will allow for even faster response times.About GenesysGenesys® empowers more than 8,000 organizations worldwide to create the best customer and employee experiences. With agentic AI at its core, Genesys Cloud™ is the AI-Powered Experience Orchestration platform that connects people, systems, data and AI across the enterprise. As a result, organizations can drive customer loyalty, growth and retention while increasing operational efficiency and teamwork across human and AI workforces. www.genesys.com/ja-jpAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesGenesys Cloud Services, Inc. Genesys PR Office (Initial Inc.)Contacts: Hirabayashi, Nagaoka, AkiyamaTel: +81-3-5572-7334 Email: genesys_pr@vectorinc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

中国在与美国关系紧张期间支持古巴

6 2 月, 2026 admin

(SeaPRwire) - 北京已承诺支持哈瓦那应对唐纳德·特朗普总统的威胁在美国将古巴这个社会主义政府列为安全威胁后，中国表达了对古巴主权的支持。中国外交部长王毅周四在北京会见了古巴外长布鲁诺·罗德里格斯·帕里利亚。 “中国坚定支持古巴维护国家主权和安全，反对外部势力无理干涉，反对任何剥夺古巴人民生存发展权利的行径，”外交部发言人林剑会后表示。林剑补充称，中国愿“尽己所能”支持古巴。帕里利亚在X上写道，双方“确认了两个社会主义国家之间历史关系的特殊战略性质”。上周，美国总统唐纳德·特朗普宣布与古巴关系进入国家紧急状态，指控古巴与“敌对国家、跨国恐怖组织及恶意行为体”结盟。他表示，古巴与俄罗斯、中国、伊朗以及巴勒斯坦武装组织哈马斯和真主党的军事合作与接触“直接威胁”美国国家安全。 “美国对古巴共产主义政权的掠夺行为零容忍，”特朗普的行政令称。古巴总统米格尔·迪亚斯-卡内尔驳斥了这些指控。“古巴不是恐怖主义国家。古巴也不威胁美国安全。我们不庇护恐怖分子，”他周四表示。迪亚斯-卡内尔表示，古巴愿与美国“在没有压力、没有前提条件，平等和相互尊重的基础上”对话。上月，美国在对委内瑞拉总统尼古拉斯·马杜罗位于加拉加斯的官邸进行突击行动时将其绑架。马杜罗在纽约法庭受审时否认了贩毒和武器指控。特朗普和美国国务卿马尔科·鲁比奥还对哥伦比亚和尼加拉瓜的左翼政府发出威胁。特朗普本周在白宫接待了哥伦比亚总统古斯塔沃·佩特罗，双方领导人称会面气氛友好。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

斯塔默与和爱泼斯坦有关联的前工党成员划清界限

5 2 月, 2026 admin

(SeaPRwire) - 彼得·曼德尔森（Peter Mandelson）因涉嫌向已故恋童癖者泄露机密信息而被怀疑滥用职权英国首相基尔·斯塔默（Keir Starmer）在新公布的文件揭露前工党（Labour Party）同僚彼得·曼德尔森（Peter Mandelson）与已定罪的性犯罪者杰弗里·爱泼斯坦（Jeffrey Epstein）的关系后，对其进行了严厉批评。首相称，他被自己在2024年任命为美国大使的人欺骗了。本周早些时候，美国司法部（US Department of Justice）公布的文件显示曼德尔森从这位已故恋童癖者那里收到了7.5万美元，随后他辞去了工党的职务以及上议院（House of Lords）的席位。他仍否认有任何不当行为，称自己不记得曾收到过这笔钱。上周公布的同一批爱泼斯坦文件还显示，曼德尔森在2009年和2010年担任当时工党政府的重要人物期间，曾向爱泼斯坦泄露机密政府文件。这些爆料促使英国警方对这位前官员涉嫌滥用职权的行为立案调查。 “我被骗了，”斯塔默在周四回应有关他在曼德尔森与爱泼斯坦的联系已为人所知的情况下仍任命其为美国大使的批评时表示。“我理解工党议员们的愤怒和失望，”他说，并补充道：“曼德尔森认识爱泼斯坦的事已经公开一段时间了，但我们没人知道这种关系的深度和黑暗程度。” 首相还表示，他原本想公布2024年收到的关于曼德尔森的安全审查建议，但由于警方要求不要做任何可能影响对这位前大使正在进行的调查的事情，他放弃了这个想法。一位保守党（Conservative Party）发言人要求对曼德尔森2024年的任命进行独立调查。“基尔·斯塔默（Keir Starmer）及其幕僚长尽管知道曼德尔森与爱泼斯坦的关系，仍任命他为大使，并且在针对他的证据越来越多时仍拒绝采取行动，”该官员表示。去年，在曝出曼德尔森写给“最好的朋友”爱泼斯坦的一封十页“情书”后，斯塔默解雇了他。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

OpenAI新模型在编码能力上实现飞跃，但引发前所未有的网络安全风险

5 2 月, 2026 admin

(SeaPRwire) - OpenAI认为，它终于在人工智能领域最受关注的竞赛之一——AI辅助编程——中取得了领先。其最新模型GPT-5.3-Codex相较于竞争对手的系统取得了坚实的进步，在编码基准测试和报告结果上显示出明显高于OpenAI和Anthropic早期各代模型的性能，这表明其在一个可能重塑软件构建方式的类别中获得了长期寻求的优势。但该公司正在以异常严格的控制措施推出该模型，并推迟了开发者的完全访问权限，因为它面临着一个更严峻的现实：正是那些使GPT-5.3-Codex在编写、测试和推理代码方面如此高效的能力，也引发了严重的网络安全担忧。在构建最强大编码模型的竞赛中，OpenAI一头撞上了发布它所带来的风险。 GPT-5.3-Codex已向付费ChatGPT用户开放，他们可以通过OpenAI的Codex工具和ChatGPT界面，将该模型用于日常软件开发任务，如编写、调试和测试代码。但目前，该公司并未开放针对高风险网络安全用途的无限制访问，OpenAI也没有立即启用允许大规模自动化使用该模型的完整API访问权限。那些更敏感的应用被置于额外的安全防护措施之后，包括一项针对经过审查的安全专业人员的新可信访问计划，这反映了OpenAI的观点，即该模型已经跨越了一个新的网络安全风险阈值。该公司在周四随模型发布的一份声明中表示，虽然没有"确凿证据"表明新模型能够完全自动化网络攻击，"但我们正在采取预防性措施，并部署迄今为止最全面的网络安全安全堆栈。我们的缓解措施包括安全培训、自动监控、高级功能的可信访问，以及包含威胁情报的强制执行流程。" OpenAI首席执行官Sam Altman在社交媒体上就这些担忧发文称，GPT-5.3-Codex是"我们第一个在我们的准备框架中网络安全风险等级达到'高'的模型"，这是OpenAI用于模型发布的内部风险分类系统。换句话说，这是OpenAI认为第一个在编码和推理方面足够出色，以至于可能实质性促成现实世界网络危害的模型，尤其是在自动化或大规模使用的情况下。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

德米特里·特列宁：战略稳定如今依赖于恐惧

5 2 月, 2026 admin

(SeaPRwire) - 军备控制已结束，真正的核秩序即将到来 2026年2月5日，星期四。这一天，俄美《削减战略武器条约》（START）到期。虽然这在象征意义上为长达50年的核军备控制篇章画上了句号，但实际上，俄美在这一领域有意义的谈判时代早已结束。原因既有客观的，也有政治的。全球地缘政治发生了巨大变化。核多极化如今已成现实。先进的常规武器能够达成曾经只有核武器才能实现的战略效果。网络空间、外层空间甚至生物技术领域都开辟了新的对抗领域。以往对弹头和运载系统的数量限制已与军事现实脱节。决定性的主观因素是，华盛顿越来越不愿意受在不同历史背景下——冷战后期及其余波中所做承诺的约束。军备控制常常被等同于战略稳定。这只在一定程度上是正确的。对核武库可核查的限制确实能使军事规划更具可预测性，并降低误判风险。但条约并不能保证和平。 2022年春天，当《新削减战略武器条约》（New START）仍在形式上有效时，美国公开宣称其目标是在乌克兰代理冲突中给俄罗斯造成战略失败。与此同时，华盛顿提议就“战略稳定”进行磋商。实际上，美国试图在常规战争中削弱一个核超级大国，同时保留能使其免受冲突升级后果影响的军备控制机制。这种矛盾暴露了旧框架的空洞。随着双边军备控制体系如今实际上已不复存在，许多人警告会出现新的核军备竞赛甚至战争。末日时钟越来越接近午夜。然而，人们必须记住：从一开始，军备控制就只约束了两个国家的首都。莫斯科和华盛顿受到限制，而英国、法国和中国的核力量从未受到约束。以色列、印度、巴基斯坦或朝鲜的核力量也未受到约束。与此同时，美中竞争正在加剧。印度和巴基斯坦再次试探对抗的极限。以色列和美国仍将重点放在伊朗的核能力和导弹能力上。在欧洲，英国和法国奉行的政策有可能与俄罗斯发生直接军事摩擦。在21世纪，战略稳定不能再用两个大国之间的大致均势或对特定武器具有法律约束力的上限来定义。它首先取决于大国，尤其是核大国是否没有发动战争的动机。旧的俄美模式不能简单地套用到有九个核国家的世界。美国战略家谈到了涉及美国、俄罗斯和中国的“三体问题”。但这个三角关系只是其中之一：亚洲的中国 - 印度 - 巴基斯坦，以及欧洲的俄罗斯 - 英国 - 法国，也是其他三角关系。这个战略难题没有全面的解决方案。但这并不意味着稳定是不可能的。这需要持续的双边和多边对话、透明措施以及永久的沟通渠道。防止意外冲突的机制至关重要。就具体问题达成的有限协议和并行的单边承诺也可能发挥作用。然而，核心内容与半个世纪前相比并未改变。战略稳定最终依赖于可靠的核威慑：拥有足够的核武库，并在必要时展示出使用它的意愿。尽管“威慑”这个词可能让人不舒服，但它仍然是核大国之间和平的基础。本文最初由发表，由今日俄罗斯（RT）团队翻译和编辑。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

特朗普就延长New START条约发表评论

5 2 月, 2026 admin

(SeaPRwire) - 总统表示，美国核专家应该着手制定一项全新的“现代化”协议。美国总统唐纳德·特朗普将美俄之间的《新削减战略武器条约》（New START）斥为一项“谈判糟糕的协议”，转而呼吁美国核专家开始着手制定一项全新的协议。这项战略军备控制协议于2月5日正式到期，引发了莫斯科和联合国的担忧。Axios同日报道称，美俄官员同意在阿布扎比举行的乌克兰和平谈判间隙对该协议进行“更新”。特朗普周四在Truth Social上写道：“我们不应延长‘新削减战略武器条约’（New START）……而应该让我们的核专家着手制定一项全新的、更完善的、现代化的条约，使其能够在未来长期发挥作用。”他还声称该协议正遭到“严重违反”。特朗普发文后不久，白宫发言人卡罗琳·莱维特（Karoline Leavitt）对记者表示，美国计划与俄罗斯讨论一项新条约。她还否认了莫斯科和华盛顿就遵守已到期条约的条款达成了任何临时协议。该条约于2010年签署，对可部署的战略核弹头和发射器数量进行了限制，并为俄罗斯和美国的核武库建立了监测机制。该条约原定于2021年到期，但当时延长了五年。 2023年，莫斯科暂停了该条约的核查机制，理由是乌克兰对俄罗斯核威慑力量的部分设施发动了袭击，并指责西方积极参与其中。不过，目前尚无任何一方违反条约规定限制的报道。周四早些时候，克里姆林宫发言人德米特里·佩斯科夫（Dmitry Peskov）表示，莫斯科曾提议再遵守该条约条款一年，但这一倡议“未得到回应”。联合国秘书长安东尼奥·古特雷斯（Antonio Guterres）呼吁美俄就后续框架进行谈判，并警告称，目前核冲突的风险处于数十年来的“最高水平”。特朗普此前曾表示，他希望达成一项“更好”的协议，将中国纳入其中。周四，佩斯科夫表示，中国认为参与新条约的谈判“毫无意义”，因为中国的核武库与美俄的核武库规模不匹配。他补充道：“我们尊重这一立场。” 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

特朗普承认移民打击行动在死亡事件后需要更“温和的方式”

5 2 月, 2026 admin

(SeaPRwire) - 美国总统表示，上个月联邦特工杀害蕾妮·古德（Renee Good）和亚历克斯·普雷蒂（Alex Pretti）的行为没有任何正当理由美国总统唐纳德·特朗普（Donald Trump）承认，上个月联邦特工在明尼阿波利斯（Minneapolis）的行动中枪杀两名美国公民后，移民执法工作可以采用“更温和的手段”。这些枪击事件引发了针对持续移民镇压行动的新一轮抗议浪潮。在周四发布的 NBC News 采访中，特朗普被问及从明尼苏达州的事件中学到了什么。 “或许我们可以稍微温和一点，但仍然必须保持强硬，”他说。总统强调，由美国移民与海关执法局（US Immigration and Customs Enforcement，ICE）主导的驱逐行动针对的是“真正的重罪犯”。当被问及杀害古德和普雷蒂是否具有正当性时，他回应道：“没有。这种事本不应该发生。” “我对这两起事件不满意……没人会满意，ICE 也不满意，”他表示，同时强调尽管如此，他必须支持执法部门。枪击事件引发骚乱后，白宫将负责明尼苏达州移民执法的官员从美国边境巡逻队（US Border Patrol）指挥官格雷戈里·博维诺（Gregory Bovino）替换为特朗普的边境事务负责人汤姆·霍曼（Tom Homan）。总统将这次人事调整描述为“缓和”该州紧张局势的举措。周三，霍曼宣布政府将撤出部署在明尼苏达州的 700 名联邦特工（约占总部署人数的四分之一）。他在新闻发布会上表示，全面撤军的前提是“地方当局持续合作，且针对 ICE 和边境巡逻队的暴力行为、言论攻击有所减少”。他周四告诉 Fox News，“大规模驱逐行动将继续进行”。民主党议员要求对 ICE 进行重大改革，其中包括为联邦特工制定行为准则、要求特工出示身份证明等。这些诉求上周导致国会一项重大预算方案陷入停滞，迫使联邦政府进入持续近一周的部分停摆状态，该状态于周三结束。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。

金属是新的石油，JD Vance向美推介：”没有什么比关键矿物更真实”

5 2 月, 2026 admin

(SeaPRwire) - 随着美国经济和未来增长的基础越来越多地建立在数字资产之上，特朗普政府希望提醒美国人，那些看得见、摸得着的商品仍然非常重要。过去的总统曾试图通过关注全球交易量最大的实物商品——石油的基本面，来引导市场远离投机行为。但对于特朗普及其官员来说，另一种有形商品已经变得太过重要，不容忽视。 “没有什么比石油更真实的东西——我还要补充一点，没有什么比关键矿物更真实的东西，”副总统JD·万斯周三。万斯正在向来自55个国家的部长们发表讲话，这些国家本周聚集在华盛顿，讨论建立一个关键矿物贸易集团。这样的伙伴关系旨在削弱中国对关键元素采矿业的扼制，这些元素对从智能手机到电动汽车再到战斗机的一切都至关重要——这些具有非常真实经济价值的基础，其战略重要性可与石油相媲美。特朗普已采取重大措施，增加美国在全球关键矿物市场中的影响力，这些矿物包括钴和锂以及有价值的稀土金属。本月，除了与盟友建立以矿物为重点的贸易集团外，政府还宣布了原材料的，在过去几个月里，政府已在稀土和矿物的多个供应商中。所有这些都是减少美国对中国依赖战略的一部分，中国掌握着关键矿物采矿和加工的，在中美贸易战中一直不惮于。 “我们许多人在过去一年里，在某些方面，已经艰难地认识到我们的经济在多大程度上依赖这些关键矿物，”万斯在演讲中说。弥补失地万斯认为，这些材料的重要性和价值可能优于近年来吞噬了美国大量投资的庞大数字经济。人工智能、云计算以及为其提供动力所需的相关数据中心基础设施正在主导私人投资和GDP增长。去年，五家美国大型科技公司的资本支出总计为，据分析师称，他们还警告说，对人工智能相关领域的投资已成为GDP增长的“关键”，“没有保证回报”。去年第一季度，人工智能占了。 “尽管数据中心、技术以及我们正在努力的所有这些令人难以置信的事情很重要，但从根本上说，你仍然拥有一个运行在实物之上的经济，”万斯说。凭借其矿物储备和在行业巨头中扩大的股份，美国已开始将更多政府资金导向采矿业，但中国在这方面仍然领先。去年，中国在海外金属和采矿项目中投资了创纪录的，作为其在中亚和非洲不断增长的“一带一路”投资组合的一部分。美国寻求协作努力这已经不是第一次有政府推动市场关注有形商品。2008年，在总统任期开始时，巴拉克·奥巴马经常人为抬高价格。奥巴马收紧了一个漏洞，该漏洞使能源期货交易员免受一些联邦监管和法规的约束，他认为投资者的“过度投机”导致了消费者汽油价格飙升。他的是更多资金用于监控石油期货交易，并对被发现操纵石油市场的人处以更高的惩罚。万斯甚至更进一步，为其关键矿物框架寻找历史类比。他提到了华盛顿能源会议，该会议寻求在石油禁运之后建立共同的能源政策，该禁运在过去一年里给石油消费国造成了经济浩劫。会议的目标是缓解价格上涨和供应短缺，这是一个特别痛点，因为禁运是由中东和北非的一个小产油国俱乐部实施的。 “那次会议发生在全球能源供应集中、市场扭曲的时刻，获取单一关键资源——当时当然是石油——已成为政治压力的工具，”万斯说。五十年后，关键资源变成了岩石和矿物，而集中几乎完全掌握在美国的一个强大经济对手手中。在峰会上，特朗普官员讨论了与合作伙伴和盟友加强合作，以强化供应链抵御来自中国的潜在冲击，提出了一系列潜在的市场机制来实现这一目标，包括参与国之间的价格下限。 “如果我们共同建设，整个努力将更加强大，更具竞争力，”万斯说。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。